Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Mina Nikanjam Clear advanced filters

  • A molecular tumor board (MTB) is often used as a platform that integrates clinical and molecular parameters for clinical decision making. Here, the authors review the outcome of 715 cancer patients presented at their institution’s MTB, and demonstrate that patients who received a MTB-recommended regimen received therapy that was better matched to their alterations and achieved better clinical outcomes.

    • Shumei Kato
    • Ki Hwan Kim
    • Razelle Kurzrock
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-9

  • Multiple tumour-agnostic kinase inhibitors have been approved that are clinically effective regardless of tumour location. This Review describes the origins of tumour-agnostic drug development, focusing on small-molecule inhibitors that target kinase pathway aberrations, and discusses the challenges in developing tissue-agnostic agents.

    • Jacob J. Adashek
    • Mina Nikanjam
    • Razelle Kurzrock
    Reviews
    Nature Reviews Drug Discovery
    Volume: 24, P: 504-520